Labiotech.eu

News and Trends 12 May 2015

Alexion will invest €450 million to expand to Dublin

Alexion Pharmaceuticals will travel across the ocean to build its first ever biologics manufacturing facility outside the United States. This €450 million, four-year project, will be constructed at the Alexion’s College Park site in Blanchardstown (Ireland) and should create approximately 200 additional full-time jobs. This will bring Alexion’s total workforce in Ireland to almost 500 employees. […]

May 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 May 2015

US-based Juno Therapeutics purchased a German biotech

Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich and Göttingen, Germany. The acquired technologies will support the development of the next generation CAR-T and TCR-T products, bringing Juno one step closer to beating cancer. The transaction further underlines Juno’s strategy of becoming a world leader in process development and in […]

May 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 May 2015

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Cambridge-based PhoreMost has been selected to receive a funding award of €1.96M (£1.4 million) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers. The British company that aims to provide low-priced and more diversed therapeutics, has developed ‘Site-Seeker’, a next-generation phenotypic screening platform based on PhoreMost’s Protein […]

May 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 May 2015

Ecrins Therapeutics’ first fundraising entirely crowdfunded by WiSEED

Ecrins Therapeutics, the company we interviewed last week, has successfully finished its first crowdfunding fundraiser, reaching €535k on WiSEED’s platform. The capital will allow the company to launch the large-scale chemical synthesis and regulatory toxicology studies, essential groundwork for the start of clinical Phase I/IIa. A second fundraise is already programmed in 2016 to finance […]

May 11, 2015 - 4 minutesmins - By Marie Godar

News and Trends 11 May 2015

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest […]

May 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 10 May 2015

Succesful Phase III for Indivior’s Schizophrenia treatment

Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment for schizophrenia. Based on these successful outcomes, the company expects to submit a New Drug Application to the U.S. FDA for potential approval in 2017. Schizophrenia is a chronic, severe and disabling brain disorder that affects an estimated 26 million […]

May 10, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 8 May 2015

MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

MorphoSys has acquired the Dutch biopharmaceutical company Lanthio Pharma. Morphosys already held 19.98% of Lanthio Pharma and will now pay €20M to purchase all outstanding shares. Thanks to the transaction MorphoSys can add Lanthio Pharma’s lead compound, LP2, to its growing proprietary portfolio. The compound, a novel lanthipeptide in development for diabetic nephropathy and fibrotic […]

May 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 May 2015

Versantis, using liposomes technology to detoxify the body

What happens when your liver stops working? The toxins your body continuously produces will no longer be eliminated, transforming your own body in a remarkable poison factory. This problem, in reality, is quite common. Liver diseases affect more than 30 million Europeans, and kill more people than both diabetes and road accidents combined! Versantis, a Swiss based biotech […]

May 7, 2015 - 5 minutesmins - By Joachim Eeckhout

News and Trends 7 May 2015

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Omeicos Therapeutics has appointed Dr. Ulrich Dauer as Chief Executive Officer. The company, that recently raised €6.2M, enrolled expert Dr. Dauer to advance on its atrial fibrillation treatment. Dr. Dauer will join Omeicos to bring additional leadership expertise as the company builds the infrastructure and capabilities needed to develop its lead therapeutic candidate for atrial […]

May 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 May 2015

Gilead acquired epigenetics-expert EpiTherapeutics

Gilead Sciences has acquired the small Danish biotech EpiTherapeutics for €57M. The epigenetics-expert has generated a library of small molecule inhibitors of gene transcription regulation than can be used for certain cancer treatments. The American company announced the signing of a definitive agreement to purchase the Danish company for €57M. EpiTherapeutics is developing innovative cancer […]

May 7, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 7 May 2015

Is the Biotech sector facing the issues of the Pharma Industry?

Currently, the pharma industry is going through a serious crisis, as the sector needs to review its economic model. On the other hand, the biotech sector often considered as the best way to innovate seems less promising than expected when it comes to putting drugs up on the market. Knowing this, it is likely that the biotech industry will face […]

May 7, 2015 - 5 minutesmins - By Nicolas Sainte-Foie

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alexion will invest €450 million to expand to Dublin

US-based Juno Therapeutics purchased a German biotech

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Ecrins Therapeutics’ first fundraising entirely crowdfunded by WiSEED

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Succesful Phase III for Indivior’s Schizophrenia treatment

GSK sparks off the Gene Therapy resurgence

MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company

Versantis, using liposomes technology to detoxify the body

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Gilead acquired epigenetics-expert EpiTherapeutics

Is the Biotech sector facing the issues of the Pharma Industry?

Subscribe to our newsletter to get the latest biotech news!

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!